The medication is a generic version of Wyeth’s Tazocin, an injectable antibiotic. Hospira will offer piperacillin/tazobactam as a powder for solution for injection or infusion in 2.25g and 4.5g single-dose vials. Hospira expects to launch piperacillin/tazobactam in other European markets in the coming months.
Piperacillin/tazobactam is a broad-spectrum antibiotic used to treat patients with moderate to severe infections. It is an injectable combination product that consists of piperacillin (an extended-spectrum penicillin) and tazobactam (a beta-lactamase inhibitor).
Michael Kotsanis, president for Europe, Middle East and Africa at Hospira, said: “The launch of Hospira’s piperacillin/tazobactam will contribute to significant price declines across the EU brought about by the availability of generic versions of Tazocin. This furthers our goal of taking costs out of the healthcare system by providing high-quality, lower-cost alternatives to proprietary medications.”